Clinical Trial - Trial ChiCTR2200058323
Access comprehensive clinical trial information for ChiCTR2200058323 through Pure Global AI's free database. This Not Applicable trial is sponsored by Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine and is currently Not yet recruiting. The study focuses on colorectal cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Tirelizumab: 200mg, given intravenously on the first day of each cycle, once every three weeks, for continuous administration until disease progression, intolerance to toxicity, or voluntary withdrawal of informed consent. Furoqueitinib: 5mg orally, once daily for 2 weeks, stopped for 1 week, every 3 weeks, continuously administered until the subject develops disease progression, intolerance to toxicity, or voluntary withdrawal of informed consent. Microwave ablation: the microwave power was 120W, the temperature was (90±10) ℃, and the ablation lasted for 8-11 minutes. The ablation range was expanded 1~2cm outward from the lesion.
Sponsor & Location
Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine
Self financing
Timeline & Enrollment
Not Applicable
N/A
Mar 31, 2024
ICD-10 Classifications
Data Source
Chinese Clinical Trial Registry
ChiCTR2200058323
Non-Device Trial